Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center stu
- PDF / 541,912 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 0 Downloads / 180 Views
RESEARCH ARTICLE
Open Access
Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study Meng Xiao1,2,3†, Jing-jing Huang1,2,3†, Ge Zhang1,2, Wen-hang Yang1,2, Fanrong Kong4, Timothy Kudinha5,6† and Ying-chun Xu1,2*†
Abstract Background: Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens. The objective of this study was to evaluate the antibacterial activity of omadacycline against recently collected bacterial isolates from Chinese patients. Results: Omadacycline showed potent activity against all Gram-positive pathogens: S. aureus MICs were low regardless of susceptibility to methicillin (methicillin-resistant Staphylococcus aureus, MRSA: N = 97, MIC50/90 0.12/0.25 mg/L, 98.5% susceptible; methicillin-sensitive Staphylococcus aureus, MSSA: N = 100, MIC50/90 0.12/0.12 mg/L, 100.0% susceptible). Omadacycline was also very effective against β-haemolytic streptococci (MIC50/90, 0.06/0.12 mg/L), viridans group streptococci (MIC50/90, 4 mg/L) K. pneumoniae and E. coli isolates (62.5 and 86.8% inhibited at ≤4 mg/L, respectively) compared to ceftazidime-susceptible isolates (77.6 and 96.1% inhibited at ≤4 mg/L, respectively). Carbapenemase-producing/
Xiao et al. BMC Microbiology
(2020) 20:350
Page 3 of 9
Table 1 Antimicrobial activity of omadacycline against Gram-positive cocci organisms Organism/organism group (number of isolates)
Number (cumulative %) of isolates at MIC (mg/L) of: 4 mg/L) [34]. E. coli, K. pneumoniae and Proteus mirabilis isolates were screened for ESBL production using the disk diffusion method as per CLSI document M100-S29, screening criteria for potential ESBL production, i.e., ceftazidime (30 μg), cefotaxime (30 μg), with / without clavulanate (10 μg) [27]. Carbapenemase-producing E. coli and carbapenemase-producing K. pneumoniae were phenotypically resistant to carbapenems but the production of carbapenemase enzymes was not confirmed. Acknowledgments The co-principal investigators in the 25 hospitals providing 1273 nonduplicate bacterial stains between January 2014 and December 2017 are as follows: (1) Ying-chun Xu, Peking Union Medical College Hospital, Beijing; (2) Chun-xia Yang, Beijing Chao-Yang Hospital, Capital Medical University. Beijing; (3) Qiong Duan, Jilin Province Hospital, Changchun, Jilin Province; (4) Yong Wang, Shandong Provincial Hospital, Qingdao, Shandong Province; (5) Kang Liao, The First Affiliated Hospital of Zhongshan University, Guangzhou, Guangdong Province; (6) Yun-song Yu, Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Hangzhou, Zhejiang Province; (7) An-hua Wu, Xiangya Hospital Central South University, Changsha, Hunan Province; (8) Hai-shen Kong, The First Affiliated Hospital of the Zhejiang University School of Medicine, Hangzhou, Zhejiang Province; (9) Weiping Wang, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiang
Data Loading...
